軸性脊椎関節炎（axSpA）の世界市場レポート 2025年

軸性脊椎関節炎（axSpA）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.3％で90億5,000万米ドルに成長します。予測期間の成長は、バイオマーカー同定、テーラーメイド治療、デジタルヘルス統合、治療選択肢の拡大、ヘルスケア政策支援などの進歩に起因すると考えられます。予測期間の主な動向には、早期介入戦略、患者中心のケア、遠隔医療と遠隔診察、疾患メカニズムの調査、意思決定の共有などがあります。

脊椎関節炎の有病率の上昇は、軸性脊椎関節炎（axSpA）市場の成長の原動力になると予想されます。脊椎関節炎は、主に脊椎や仙腸関節などの軸索骨格に影響を及ぼす慢性疾患で、高齢化や軽度の転倒や事故による脊椎損傷に関連した症例が増加しています。様々な治療法は、疼痛の管理、炎症のコントロール、axSpAを患う人の生活の質の向上を目的としています。例えば、関節炎患者を支援する英国の慈善団体であるVersus ArthritisのMusculoskeletal Health Report 2023によると、2022年には約6万人が腋窩脊椎関節炎に罹患し、毎年約2,200人の成人がこの疾患と診断されています。したがって、腋窩脊椎関節炎の有病率の上昇は、axSpa市場の成長を促進する重要な要因です。

高齢化の進展は、今後の軸性脊椎関節炎（axSpA）市場の拡大を牽引すると予測されます。高齢化とは、人口動態の変化により人口に占める高齢者の割合が増加することを指します。高齢者のaxSpAの治療には、関節機能や可動性の改善、QOLの向上、脊髄構造損傷の予防、医療費の削減、障害の予防、治療アプローチの最適化など、いくつかのメリットがあります。例えば、2022年10月、世界保健機関（WHO）は、2030年までに世界の6人に1人が60歳以上になり、この数字は2050年までに2倍の21億人になると予測していると報告しました。さらに2023年7月、英国を拠点とする慈善団体Age UKは、イングランドには現在1,100万人の65歳以上の高齢者がおり、今後5年間で10％、2043年までに32％、それぞれ110万人と350万人の増加が予測されると指摘しました。その結果、高齢化人口の増加が軸性脊椎関節炎（axSpA）市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界軸性脊椎関節炎（axSpA） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の軸性脊椎関節炎（axSpA）市場：成長率分析
• 世界の軸性脊椎関節炎（axSpA）市場の実績：規模と成長, 2019-2024
• 世界の軸性脊椎関節炎（axSpA）市場の予測：規模と成長, 2024-2029, 2034F
• 世界軸性脊椎関節炎（axSpA）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の軸性脊椎関節炎（axSpA）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 強直性脊椎炎（AS）
• 非放射線学的軸性脊椎関節炎（nr-axSpA）
• 世界の軸性脊椎関節炎（axSpA）市場商業化された治療法によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗腫瘍壊死因子療法（TNF）
• 抗インターロイキン療法（IL）
• 抗ヤヌスキナーゼ療法（JAK）
• 世界の軸性脊椎関節炎（axSpA）市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 注射
• 世界の軸性脊椎関節炎（axSpA）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）アルファ阻害剤
• 非ステロイド性抗炎症薬（NSAID）
• 従来の疾患修飾抗リウマチ薬
• グルココルチコイド
• インターロイキンブロッカー
• 世界の軸性脊椎関節炎（axSpA）市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の軸性脊椎関節炎（axSpA）市場強直性脊椎炎（AS）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 初期AS
• 進行期AS
• 世界の軸性脊椎関節炎（axSpA）市場非放射線学的軸性脊椎関節炎（nr-axSpA）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 症状のあるnr-axSpA
• 無症候性nr-axSpA

第7章 地域別・国別分析

• 世界の軸性脊椎関節炎（axSpA）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の軸性脊椎関節炎（axSpA）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 軸性脊椎関節炎（axSpA）市場：競合情勢
• 軸性脊椎関節炎（axSpA）市場：企業プロファイル
  • Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A
• Bristol-Myers Squibb Company
• AstraZeneca plc.
• Abbott Laboratories
• GSK plc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• UCB S.A.
• Boehringer Ingelheim International GmbH.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 軸性脊椎関節炎（axSpA）市場2029：新たな機会を提供する国
• 軸性脊椎関節炎（axSpA）市場2029：新たな機会を提供するセグメント
• 軸性脊椎関節炎（axSpA）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition primarily affecting the axial skeleton, including the spine and sacroiliac joints, leading to persistent back pain and stiffness. The condition is characterized by inflammation in the sacroiliac joints.

The main types of axial spondyloarthritis (axSpA) include Ankylosing Spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Ankylosing Spondylitis (AS) is a specific form of arthritis that affects the ligaments and joints in the spine. Commonly used over-the-counter anti-inflammatory medications, such as naproxen and ibuprofen, are often employed to alleviate pain, inflammation, and muscle stiffness, with the goal of delaying complications and spinal deformities. Various commercialized therapies are available for the treatment of axial spondyloarthritis, including anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). These therapies come in different dosage forms, such as tablets and injections, and are utilized for different types of treatments, including tumor necrosis factor (TNF) alpha inhibitors, non-steroidal anti-inflammatory drugs (NSAID), conventional disease-modifying anti-rheumatic drugs, glucocorticoids, and interleukin blockers. These treatments are distributed through different channels, including hospital pharmacies, retail pharmacies, and online pharmacy stores.

The axial spondyloarthritis (axSpA) market research report is one of a series of new reports from The Business Research Company that provides axial spondyloarthritis (axSpA) market statistics, including axial spondyloarthritis (axSpA) industry global market size, regional shares, competitors with an axial spondyloarthritis (axSpA) market share, detailed axial spondyloarthritis (axSpA) market segments, market trends and opportunities, and any further data you may need to thrive in the axial spondyloarthritis (axSpA) industry. This axial spondyloarthritis (axSpA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $6.08 billion in 2024 to $6.58 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress

The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $9.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.

The rising prevalence of spondyloarthritis is expected to be a driving force behind the growth of the axial spondyloarthritis (axSpa) market. Spondyloarthritis, a chronic condition primarily affecting the axial skeleton, such as the spine and sacroiliac joints, has seen an increase in cases linked to the aging population and spinal injuries resulting from minor falls or accidents. Various treatments aim at managing pain, controlling inflammation, and improving the quality of life for individuals suffering from axSpA. For example, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity supporting people with arthritis, approximately 60,000 individuals were affected by axial spondyloarthritis in 2022, with around 2,200 adults diagnosed annually with this condition. Hence, the rising prevalence of axial spondyloarthritis is a significant driver fueling the growth of the axSpa market.

The growing aging population is anticipated to drive the expansion of the axial spondyloarthritis (axSpA) market in the future. An aging population refers to a demographic shift where the proportion of elderly individuals within a population increases. Managing axSpA in older adults offers several benefits, including improved joint function and mobility, enhanced quality of life, prevention of spinal structural damage, reduced healthcare costs, prevention of disability, and optimized treatment approaches. For instance, in October 2022, the World Health Organization reported that by 2030, 1 in 6 people globally will be aged 60 or older, with this figure expected to double to 2.1 billion by 2050. Furthermore, in July 2023, Age UK, a UK-based charity, noted that there are currently 11 million people over the age of 65 in England, with this number projected to rise by 10% over the next five years and by 32% by 2043, equating to increases of 1.1 million and 3.5 million people, respectively. As a result, the rising aging population is fueling the growth of the axial spondyloarthritis (axSpA) market.

Product innovation stands out as a leading trend gaining traction in the axial spondyloarthritis (axSpA) market. Key companies in this field are actively developing novel drugs to maintain their market standing. For instance, in June 2023, UCB SA, a pharmaceutical company based in Belgium, obtained marketing authorization from the New European Commission for BIMZELX (bimekizumab). This medication is designed for treating active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) in adults exhibiting objective signs of inflammation indicated by elevated C-reactive protein. These approvals within the European Union represent the first global marketing authorizations for the treatment of axial spondyloarthritis using this drug.

Significant investments are a focal point for major companies operating in the axial spondyloarthritis (axSpA) market to gain a competitive advantage. Notably, the investment revolves around the development of Izokibep, a unique IL-17A inhibitor intended for managing inflammatory diseases such as psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). For example, in September 2022, Acelyrin Inc., a biopharmaceutical company based in the US, announced a $300 million investment. Izokibep, a mimetic antibody simulating interleukin-17A (IL-17A), aims to overcome the limitations of monoclonal antibodies and has shown promising tolerability in clinical trials. This substantial investment is directed towards securing potential approvals for Izokibep as a treatment for various inflammatory conditions and advancing its clinical development. The company's commitment to pioneering immunology therapies and addressing unmet medical needs in treating inflammatory disorders is evident through its emphasis on securing significant funding and advancing the development of Izokibep.

In April 2022, Ampersand Health, a UK-based research company, entered into a partnership with UCB SA for an undisclosed amount. This collaboration is intended to benefit patients dealing with axial spondyloarthritis (axSpA) by leveraging the innovative digital solutions from Ampersand Health and the clinical expertise of UCB SA. The aim of the partnership is to enhance the management of symptoms for individuals with axial spondyloarthritis and improve their overall quality of life. UCB SA, the Belgium-based biopharmaceutical company involved in neurology and immunology therapies, is known for providing solutions in the field of axial spondyloarthritis.

Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC

North America was the largest region in the axial spondyloarthritis (axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the axial spondyloarthritis (axspa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The axial spondyloarthritis (axSpA) market consists of revenues earned by entities by providing physical examinations, blood tests, magnetic resonance imaging (MRI) scans, and X-ray scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The axial spondyloarthritis (axSpA) market also includes sales of analgesics, biologics, ibuprofen, naproxen, and diclofenac. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Axial Spondyloarthritis (axSpA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on axial spondyloarthritis (axspa) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for axial spondyloarthritis (axspa) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The axial spondyloarthritis (axspa) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Ankylosing Spondylitis (AS); Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
• 2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF); Anti-Interleukin Therapy (IL); Anti-Janus Kinase Therapy (JAK)
• 3) By Dosage Form: Tablets; Injections
• 4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors; Non-Steroidal Anti-Inflammatory Drugs (NSAID); Conventional Disease Modifying Anti-Rheumatic Drugs; Glucocorticoids; Interleukin Blockers
• 5) By End-Use: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacy Stores
• Subsegments:
• 1) By Ankylosing Spondylitis (AS): Early-stage AS; Advanced-stage AS
• 2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA; Asymptomatic nr-axSpA
• Companies Mentioned: Johnson and Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; Merck and Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Axial Spondyloarthritis (axSpA) Market Characteristics

3. Axial Spondyloarthritis (axSpA) Market Trends And Strategies

4. Axial Spondyloarthritis (axSpA) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Axial Spondyloarthritis (axSpA) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Axial Spondyloarthritis (axSpA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Axial Spondyloarthritis (axSpA) Market Growth Rate Analysis
• 5.4. Global Axial Spondyloarthritis (axSpA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Axial Spondyloarthritis (axSpA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Axial Spondyloarthritis (axSpA) Total Addressable Market (TAM)

6. Axial Spondyloarthritis (axSpA) Market Segmentation

• 6.1. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ankylosing Spondylitis (AS)
• Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
• 6.2. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Tumor Necrosis Factor Therapy (TNF)
• Anti-Interleukin Therapy (IL)
• Anti-Janus Kinase Therapy (JAK)
• 6.3. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Injections
• 6.4. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Alpha Inhibitors
• Non-Steroidal Anti-Inflammatory Drugs (NSAID)
• Conventional Disease Modifying Anti-Rheumatic Drugs
• Glucocorticoids
• Interleukin Blockers
• 6.5. Global Axial Spondyloarthritis (axSpA) Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacy Stores
• 6.6. Global Axial Spondyloarthritis (axSpA) Market, Sub-Segmentation Of Ankylosing Spondylitis (AS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early-stage AS
• Advanced-stage AS
• 6.7. Global Axial Spondyloarthritis (axSpA) Market, Sub-Segmentation Of Non-Radiographic Axial Spondyloarthritis (nr-axSpA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Symptomatic nr-axSpA
• Asymptomatic nr-axSpA

7. Axial Spondyloarthritis (axSpA) Market Regional And Country Analysis

• 7.1. Global Axial Spondyloarthritis (axSpA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Axial Spondyloarthritis (axSpA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Axial Spondyloarthritis (axSpA) Market

• 8.1. Asia-Pacific Axial Spondyloarthritis (axSpA) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Axial Spondyloarthritis (axSpA) Market

• 9.1. China Axial Spondyloarthritis (axSpA) Market Overview
• 9.2. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Axial Spondyloarthritis (axSpA) Market

• 10.1. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Axial Spondyloarthritis (axSpA) Market

• 11.1. Japan Axial Spondyloarthritis (axSpA) Market Overview
• 11.2. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Axial Spondyloarthritis (axSpA) Market

• 12.1. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Axial Spondyloarthritis (axSpA) Market

• 13.1. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Axial Spondyloarthritis (axSpA) Market

• 14.1. South Korea Axial Spondyloarthritis (axSpA) Market Overview
• 14.2. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Axial Spondyloarthritis (axSpA) Market

• 15.1. Western Europe Axial Spondyloarthritis (axSpA) Market Overview
• 15.2. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Axial Spondyloarthritis (axSpA) Market

• 16.1. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Axial Spondyloarthritis (axSpA) Market

• 17.1. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Axial Spondyloarthritis (axSpA) Market

• 18.1. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Axial Spondyloarthritis (axSpA) Market

• 19.1. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Axial Spondyloarthritis (axSpA) Market

• 20.1. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Axial Spondyloarthritis (axSpA) Market

• 21.1. Eastern Europe Axial Spondyloarthritis (axSpA) Market Overview
• 21.2. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Axial Spondyloarthritis (axSpA) Market

• 22.1. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Axial Spondyloarthritis (axSpA) Market

• 23.1. North America Axial Spondyloarthritis (axSpA) Market Overview
• 23.2. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Axial Spondyloarthritis (axSpA) Market

• 24.1. USA Axial Spondyloarthritis (axSpA) Market Overview
• 24.2. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Axial Spondyloarthritis (axSpA) Market

• 25.1. Canada Axial Spondyloarthritis (axSpA) Market Overview
• 25.2. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Axial Spondyloarthritis (axSpA) Market

• 26.1. South America Axial Spondyloarthritis (axSpA) Market Overview
• 26.2. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Axial Spondyloarthritis (axSpA) Market

• 27.1. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Axial Spondyloarthritis (axSpA) Market

• 28.1. Middle East Axial Spondyloarthritis (axSpA) Market Overview
• 28.2. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Axial Spondyloarthritis (axSpA) Market

• 29.1. Africa Axial Spondyloarthritis (axSpA) Market Overview
• 29.2. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Commercialized Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Axial Spondyloarthritis (axSpA) Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Axial Spondyloarthritis (axSpA) Market Competitive Landscape And Company Profiles

• 30.1. Axial Spondyloarthritis (axSpA) Market Competitive Landscape
• 30.2. Axial Spondyloarthritis (axSpA) Market Company Profiles
  • 30.2.1. Johnson and Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Axial Spondyloarthritis (axSpA) Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca plc.
• 31.5. Abbott Laboratories
• 31.6. GSK plc.
• 31.7. Eli Lilly and Company
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Gilead Sciences Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Biogen Inc.
• 31.13. Vertex Pharmaceuticals Incorporated
• 31.14. UCB S.A.
• 31.15. Boehringer Ingelheim International GmbH.

32. Global Axial Spondyloarthritis (axSpA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market

34. Recent Developments In The Axial Spondyloarthritis (axSpA) Market

35. Axial Spondyloarthritis (axSpA) Market High Potential Countries, Segments and Strategies

• 35.1 Axial Spondyloarthritis (axSpA) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Axial Spondyloarthritis (axSpA) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Axial Spondyloarthritis (axSpA) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer